2022
Emerging Immunohistochemical Biomarkers for Myeloid Neoplasms.
Verma A, Xu ML. Emerging Immunohistochemical Biomarkers for Myeloid Neoplasms. Archives Of Pathology & Laboratory Medicine 2022, 147: 403-412. PMID: 35533352, DOI: 10.5858/arpa.2021-0558-ra.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkersBiomarkers, TumorDisease ProgressionHumansMyeloproliferative DisordersNeoplasmsPrognosisConceptsMyeloid neoplasmsImmunohistochemical biomarkersImmunohistochemical markersManagement of patientsNovel immunohistochemical markerPosttreatment biopsiesImmunohistochemical toolsDisease progressionCorrect diagnosisClinical scenariosNeoplasmsPatient careLiterature searchRelevant biomarkersBiomarkersImmunohistochemistryMolecular biomarkersScientific literature searchMarkersArchival samplesOriginal articlesMolecular eraCurrent eraPatientsBiopsy
2021
ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer
Sarshekeh A, Alshenaifi J, Roszik J, Manyam G, Advani S, Katkhuda R, Verma A, Lam M, Willis J, Shen J, Morris J, Davis J, Loree J, Lee H, Ajani J, Maru D, Overman M, Kopetz S. ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer. Clinical Cancer Research 2021, 27: 1663-1670. PMID: 33414133, PMCID: PMC7956157, DOI: 10.1158/1078-0432.ccr-20-2404.Peer-Reviewed Original ResearchConceptsMicrosatellite stable colorectal cancerColorectal cancerStable colorectal cancerMutant casesCancer Center databaseT-cell markersTumor mutational burdenAT-rich interactive domain 1AUnique molecular subgroupSignificant higher expressionCancer Genome AtlasImmunologic featuresIFNγ expressionImmune activationImmune subtypesTreatment strategiesPreclinical modelsT cellsImmune responseMutational burdenSeparate cohortPatientsTherapy trialsActive subgroupMolecular subgroups